Biological E seeks DCGI's nod for phase-3 trial of Corbevax as booster dose in those vaccinated with Covishield or Covax

Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month

from mint - Science https://ift.tt/3iUV5zw